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Abstract 
Heat-labile enterotoxin (LT) is one of the most important toxins produced by 
enterotoxigenic Escherichia coli (ETEC).  It consists of one A subunit (LTA) for intracellular 
enzymatic activity and five B subunits (LTB) forming a pentamer for binding to host cell 
receptors. In the last few decades, LT has been extensively studied as a strong immune 
stimulator, as well as an effective adjuvant with multiple immunomodulatory properties. To 
understand better the features of LT, we mapped B-cell linear epitopes of the enzymatic A 
subunit and explored the relationship between these epitopes and the toxicity of LT. Eleven B-
cell linear (continuous) epitopes were in silico identified based on online software. In part one of 
the study, all 11 epitopes were fused into a modified ovalbumin carrier protein respectively. Each 
recombinant fusion protein was expressed and purified, and was characterized in ELISA and 
Western Blot using the anti-LT serum. Moreover, each fusion protein was used to immunize 
mice to determine immune response specific to LT in vivo. A total of eleven epitopes were 
identified from the LTA subunit. Results showed that anti-LT serum recognized all 11 epitopes, 
while the mouse immunization study indicated that antibodies derived from epitope 7 
(105SPHPYEQEVSA115) had significantly greater anti-LT antibody titers and neutralized LT 
enterotoxicity more efficiently than the other epitopes. In part two of the study, to test whether 
individual epitope plays a role in LT toxicity, 10 epitopes in the A1 domain of LTA subunit were 
replaced by a foreign peptide respectively and the mutant LTs were examined for enterotoxicity. 
Data indicated that all these LT mutants showed enterotoxicity abolished. However, these LT 
mutants formed holotoxin structure and bound to GM1 in vitro. Results from this study indicated 
that replacement of these LT epitopes did not affect the forming of LT holotoxin structure and 
the binding to host receptors, indicating LT can serve as a safe vaccine platform to carry foreign 
  
antigens. With the immunodominant epitope 7 being kept while other LTA epitopes replaced by 
epitopes from other ETEC virulence factors, this platform can be used to construct broadly 
protective multivalent mucosal vaccines against ETEC, and perhaps as a universal platform for 
vaccines against other enteric diseases.  
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Chapter 1 - Literature Review 
 Enterotoxigenic Escherichia coli 
Enterotoxigenic Escherichia coli (ETEC) are Gram-negative bacteria which cause severe 
watery diarrhea in human and animals [1]. In 1967, Gyles and Barnum reported that enterotoxins 
in the bacterial lysates caused fluid accumulation in ligated rabbit ileal loop [2]. Moon reported 
that 40% activity of enterotoxin secreted in the culture supernatant was retained after 30 minutes 
of incubation at 65 °C, the same percentage of activity was lost after dialysis of cell-free ETEC 
products [3], indicating there were two types of enterotoxin produced by the bacteria. One is 
relatively larger in size and could be inactivated by heat, which is called heat-labile enterotoxin 
(LT). The other is much smaller and stable at 65 °C, thus is called heat-stable enterotoxin (ST). 
Both LT and ST are encoded in plasmids which can be transferred to different E. coli strain;  E. 
coli strains producing either one or both enterotoxins are called enterotoxigenic E. coli (ETEC) 
[4].  
In addition to LT and ST enterotoxins, the proteinaceous structure on the surface of 
ETEC, which are called colonization factors (CFs), also play an important role in ETEC 
pathogenesis. CFs mediate bacterial adherence to host intestinal epithelial cells and initiate 
bacterial colonization [5]. To date, more than 20 colonization factors have been identified from 
ETEC strains associated with diarrhea in humans. These CFs were further divided into different 
subgroups of colonization factor antigens (CFAs) or coli surface antigens (CS). CFs differ 
genetically, structurally and immunologically, and presented in fimbrial, fibrillar, helical or 
nonfimbrial morphology [6]. CFA/I, II, and IV were the most associated with ETEC diarrhea and 
other CFs were observed prevalent in different regions [7]. ETEC strains causing diarrhea in 
2 
animals express a variety of CFs as well, among them K88, K99, and 987P are most prevalent 
[8]. 
After attaching to host intestinal surface, ETEC produce STa (heat-stable type I toxin) 
and/or LT that stimulate intestinal ion and fluid secretion through different pathways. STa is an 
18 or 19-amino acid peptide and poorly immunogenic. STa shares similar structures with 
endogenous peptides called guanylin and uroguanylin. STa and both guanylin peptides bind to an 
intracellular receptor called guanylate cyclase C (GC-C), leading to an increasing level of 
intracellular cyclic GMP (cGMP).  Elevation of cGMP level activates the ion channels on cell 
membrane, resulting in water hypersecretion [9; 10]. LT causes diarrhea in a similar pattern, 
which first binds to cell surface through ganglioside GM1 receptors and then enters into cytosol. 
The enzymatic A subunit activates the adenylate cyclase, thus stimulates the production of cyclic 
AMP (cAMP) which further cause the malfunction of ion channels [11]. Together, these two 
enterotoxins contribute to the excess secretion of fluid and electrolytes and osmotic diarrhea.  
ETEC bacteria cause diarrhea in not only pigs, they are also responsible for lethal 
diarrhea in newborn calves, small ruminants, and other farm animals [12]. Moreover, ETEC are 
the top cause of diarrhea in humans. The first human case of ETEC infection was reported in 
1956.  Researchers isolated E. coli strains which caused diarrheal disease in a pattern similar to 
Vibrio cholerae, and found these E. coli strains were related with animal ETEC strains [13]. 
Characterized by its potent enterotoxins and the diversity of CF adhesins, ETEC is believed to be 
one of the leading cause of bacterial originated diarrhea, posing a great threat to people, 
especially children under 5 years of age in developing countries, as well as children and adults 
traveling from developed countries to developing countries [14]. Data showed that each year 
around 380,000 human deaths are related to ETEC [7]. Based on clinical data collected from 
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1970 to 1999, a child born in a developing country experienced 3-5 ETEC associated diarrheal 
episodes per year before the age of 5, and nearly 50 million children of this age group carry 
ETEC without showing any symptoms [15]. Therefore, ETEC remains one of the most important 
diarrheal pathogen among children in the developing world. Although the incidence of ETEC 
infection decreases with age, ETEC is still the most frequent diarrheal pathogens that affects 
millions of persons who travel to developing countries every year [16]. It is reported that about 
30-60% cases of travelers’ diarrhea are caused by ETEC, although most infections are self-
eliminated and don’t need special treatment, it can be risky to populations with weak or deficient 
immunity such as kids, pregnant women, and people with other pre-existing diseases [17]. 
ETEC is transmitted through contaminated food and water in areas lack of hygiene 
practice and supply of safe drinking water. The outbreak of ETEC can also happen in non-
endemic countries through food importation [18]. In some areas in South America, Africa, and 
Southeast Asia, ETEC infections manifest seasonality, with most frequent during warm periods 
of the year, suggesting travelers are more susceptible at these times. Malnutrition, which is 
common in children from developing countries, is another factor that contributes to more severe 
ETEC infection [19]. The loss of fluids and electrolytes lead to severe dehydration, therefore, 
rehydration intravenously or orally is crucial when treating ETEC diarrhea [20]. When bacterial 
infection is diagnosed in adult cases, antimicrobial treatment is another option because bacterial 
load can be effectively controlled and the duration of illness can be shortened by some 
antimicrobials [21]. However, antimicrobial treatment is not advised to   treat diarrhea in 
children, since these diseases are often caused by multiple bacterial and viral agents [22]. Due to 
over use of antibiotics, increasing numbers of antibiotic-resistant diarrheagenic E. coli including 
ETEC have rapidly spread worldwide, causing serious problems to the control of diarrheal 
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diseases in developing countries. It is reported that 86.4% of E. coli isolated from diarrheal 
children were resistant to at least three different classes of antibiotics [23]. Studies from 
Bangladesh and India have also found multiple antimicrobial resistance in ETEC isolates [24; 
25]. Rapid buildup of antibiotic resistance in ETEC bacteria alarms public health communities to 
seek other approaches to prevent and treat ETEC infection. While community- or country-wide 
sanitation system and supply of safe drinking water and good practice off food preparation and 
distribution can block the transmission of the diseases effectively [26], development of effective 
ETEC vaccines is surfaced as the leading prevention approach for ETEC prevention.    
 
 Heat-labile enterotoxins 
Heat-labile enterotoxin (LT) one of the most important virulence factors of ETEC. A 
review paper which summarized 17,205 ETEC isolates in 136 studies from 1961 to 2009 and 
showed that 60% of ETEC isolates expressed LT either alone (27%) or in combination with ST 
(33%) [7]. There are two major groups of LT. Type I LT (LT-I) has over 80% homology in 
amino acid sequence with cholera toxin (CT) expressed by Vibrio cholerae. Type II LT includes 
LT-IIa, LT-IIb, and LT-IIc, which are genetically different from LT-I and do not cross react with 
LT-I immunologically [27]. LT-I is found in both human and animal ETEC strains, while type II 
LT is mainly reported in animal associated ETEC. In this study, we will only focus on human 
LT-I, the word LT in this thesis refers to LT-I unless distinguished by Roman numbers. 
LT is a typical AB5 type toxin which is composed of one A subunit (28kDa) and five B 
subunits (11.5kDa each). The enzymatically active A subunit is composed of two domains (A1 
and A2) which are combined through a disulfide bond. The A1 domain has an ADP-
ribosyltransferase activity, while the A2 domain connects A1 to the ring-like pentameric B5 in 
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the center. Each LT-B subunit binds specifically to ganglioside (GM1) which is a group of 
glycolipids present on the surface of most eukaryotic cells [1]. After binding to the surface of 
host cells, LT is subsequently endocytosed and retrogradely transported through Golgi apparatus 
to the endoplasmic reticulum (ER). The catalytic A1 domain is then cleaved and secreted 
through the vacuolar membrane. A1 acts on the α subunit of the GTP-binding protein (Gs-α) 
located on the basolateral membrane of intestinal epithelial cells by transferring an ADP-ribosyl 
moiety from NAD to Gs-α. The activation of Gs protein stimulates its adenylate cyclase activity, 
thereby increases the level of intracellular cAMP which is an important second messenger. High 
cAMP level modulates protein kinase A and results in abnormal activation of membrane ion 
transporters. The secretion of Cl- is increased while the absorption of Na+ and Cl- are decreased, 
the abnormal ion distribution in the intestine lumen, finally result in osmotic diarrhea [11]. 
Since the 1980s, the mucosal adjuvant effect of CT has been verified. When orally co-
administered with an antigen, the adjuvant activity of CT was proved to be dose dependent [28]. 
CT acts as an adjuvant by inducing multiple Th2 cells secreting cytokines which stimulate IgG 
and secretory IgA response in mice [29]. Similar with CT, LT induces the activation of both Th1 
and Th2 cells, provides more comprehensive immune responses compared to CT [30]. However, 
the toxicity of LT and CT became an obstacle to further use these toxins in vaccine development. 
To solve this problem, a group of reduced- or non-toxic LT and CT derivations were generated 
through mutating one or several amino acids [31]. Some of them such as mutant LT (L192G, 
LTK63) [32; 33], and double mutant LT (dmLT L192G/L211A) [34] have been demonstrated to 
be less toxic and the adjuvant properties were retained. Recent research found that, even without 
the holotoxin structure, the A subunit or B subunits alone also have some immune modulatory 
abilities [35; 36].  
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To date, a variety of vaccines in combination with LT and its derivations as adjuvants 
through novel immunization routes have been reported. Lee   found dmLT helped a subunit 
vaccine targeting the tip protein of Shigella flexneri type III secretion system (T3SS) to elicit 
strong immunity in mice model [37]. Marchioro   immunized mice with LTB-fused antigens and 
LTB co-administered antigens respectively and proved that LTB effectively enhanced the host 
immune response in both ways, but the fusion protein induced significantly higher IgG level than 
co-administered antigens [36]. The addition of dmLT to inactivated Helicobacter pylori vaccine 
enhanced H. pylori specific CD4+ T cell response through the activation of DCs [38].  A live 
attenuated vaccine generated by introducing a dmLT encoded plasmid into Salmonella enterica 
serovar Enteritidis strain SE JOL1087 significantly enhanced the production of plasma IgG and 
intestinal secretory IgA in orally immunized chicken [39]. Using patch delivery system (PDS) to 
deliver recombinant birch pollen allergen Bet v1 with LT epicutaneously induced allergen-
specific IgG antibodies blocking allergic IgE in guinea pig, suggesting a promising role LT plays 
in immunotherapy against hypersensitivity and autoimmune diseases [40].  
Compared to traditional parenteral immunization routes, LT shows better immune-
stimulating abilities when administered at mucosal sites. Oral, intranasal, sublingual, and 
intradermal routes could be more feasible and effective options for LT related immunization. A 
combination of mucosal and systemic immunization further enhance the immune responses [41]. 
 
 Vaccines against ETEC 
Vaccination is believed to be the best way to prevent ETEC other than maintaining a 
sanitary environment. By now, there is one licensed cholera vaccine (Dukoral®) that provides 
only short-term protection against ETEC, which can stimulate anti-LT immunity due to the high 
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homology between LT and CT [42]. A variety of more protective ETEC vaccines are still in 
development. 
 Inactivated whole cell vaccines 
In 1988, an ETEC prototype strain H10407 which contains LT, STa, and CFA/I 
inactivated with colicin 2 was used as a vaccine candidate, and showed good protection in a 
small scale human challenge study [43]. A killed whole-cell ETEC that expressing the most 
common colonization factor antigens (CFAs), i.e., CFA/I, CFA/II, and CFA/IV, co-administered 
with 1 mg of recombinant cholera toxin B subunit (rCTB) induced IgA against both CFAs and 
CTB in the intestine after two doses of vaccine [44]. However, this vaccine was not efficacious 
in clinical trials, the protection rate was not significant and vaccination caused side effects like 
vomiting or diarrhea in children under two years old. To modify the vaccine, researchers tried to 
overexpress CFA antigens in ETEC strains so that less bacteria would be needed to induce 
immune response and thus reduce the adverse effects. Meanwhile, a non-toxic double mutant LT 
(dmLT; LTR192G/L211A) was added as an adjuvant to enhance host immune response [45]. 
Further evaluation of this vaccine candidate is still in process.  
 Live attenuated vaccines 
An ETEC mutant strain E1392/75-2A that losing LT and STa genes was the first ETEC 
strain used for live-attenuated vaccine [46]. It provided good protection in a rabbit challenge 
model, but some vaccinated human volunteers showed side effect indicated that this vaccine 
candidate had some safety issues [47]. To further attenuate the bacteria, some mutant strains 
were subsequently generated based on E1392/75-2A. PTL-002 (ΔaroCΔompCΔompF) and PTL-
003 (ΔompRΔaroC) were proved to be safe and effective in both mice and human trials [48]. One 
disadvantage of these vaccine candidates is that they only contained limited virulence factors of 
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ETEC. To obtain more broadly protection, a new live attenuated vaccine that contained three 
different ETEC strains ACAM 2025 (CFA/I, LTB), ACAM 2022 (CS5/CS6, LTB) and ACAM 
2027 (CS1/CS2/CS3, LTB) was generated which showed great potential in preventing ETEC 
that have multiple CFAs and LT [49]. 
              Instead of directly using ETEC strains as the vaccine candidate, there are several 
vectored live attenuated ETEC vaccines using bacteria other than ETEC as host strains. For 
example, an attenuated Shigella flexneri 2a strain was engineered to express ETEC CFAs and 
toxoid LT, which induced the immune response against both Shigella and ETEC [50-52]. 
Besides, ETEC vaccines using Vibrio cholerae [53], and Salmonella typhi [54] as vectors were 
also promising candidates if confirmed in further clinical trials. 
 Subunit vaccines 
ETEC subunit vaccines usually contain single or multiple purified antigens such as toxoid 
or surface molecules which are easily recognized by immune system. In most cases, adjuvant 
plays an indispensable role in helping subunit vaccines inducing immune responses effectively. 
Back in 1980s, LT was used as a vaccine through a needless transcutaneous route [55]. 
However, as a potent bacterial toxin, wild type LT causes diarrhea and it is neurotoxic when 
administered intranasally [56]. Several detoxified LT were then created by mutating one or two 
amino acids. Among them, dmLT (LTR192G/L211A) shows the best potential which maintains 
its antigenicity and abandoned toxicity. It has been successfully used as either antigen or 
adjuvant in ETEC vaccine development recently [34; 57-59]. To get a more broadly protection 
against ETEC, another enterotoxin STa should be also included in subunit vaccines. The 
combination of STa and LT by genetic fusion or chemical conjugation solved the problem of 
lack of immunogenicity when STa served as an antigen alone [60]. Substitution of some amino 
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acids in the native STa toxin reduced its toxicity while its conformational structure was retained. 
These LT-STa toxoid fusions was able to elicit antibodies to neutralize both LT and STa [61].  
CFAs are also important candidates for ETEC subunit vaccines. The major structural 
subunits, minor structural subunits, and tip adhesins of CFA are potential candidates for vaccine 
development. To include as much antigen as possible, a new multiepitope fusion antigen (MEFA) 
strategy was introduced [62]. A MEFA contains epitopes from major subunits of CFA/I/II/IV 
could induce specific antibody that inhibit the adherence of E. coli strains expressing CFA/I, and 
CS1-6 [57; 58]. Mice serum derived from another similar MEFA using tip protein epitopes 
prevented the adherence of 9 ETEC adhesins [63]. These studies provided a new approach for 
ETEC subunit vaccine development in the future. 
Some novel antigens of ETEC other than LT, ST, and CFAs were discovered recently. 
For example, EtpA and EaeH are surface adhesins required for efficient colonization of the small 
intestine in murine models [64; 65]. EatA is a protease that degrades mucin in the intestinal 
lumen, thus facilitates bacterial adhesion [66]. Another important protein YghJ, an effector 
molecule secreted by the same type II secretion system (T2SS), is responsible for LT delivery. 
Toxin secretion could be inhibited by anti-YghJ antibody in vitro [67]. These proteins could be 
possibly new targets to generate more broadly protective ETEC vaccines. 
 
 Purpose of study 
Enterotoxigenic Escherichia coli (ETEC) is one of the leading causes of diarrhea disease 
in both human and animals, which is a great threat to people especially children under five years 
old in developing countries, as well as foreigners travel to prevalent areas [7; 15]. Except for 
improving sanitary conditions, vaccination is another important way to prevent and control 
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ETEC infection. Due to the heterogeneity of virulence factors among ETEC strains, it is 
challenging to develop a broadly protective ETEC vaccine. Recently, a new multiepitope fusion 
antigen (MEFA) strategy showed a promising approach for the development of ETEC subunit 
vaccine [62]. Briefly, epitopes of different vaccine candidate antigens were selected and 
combined to generate a fusion antigen which is expected to provide effective protection against 
all of these antigens. Selecting an appropriate carrier or backbone is pivotal for the construction 
of MEFA protein. Ideal carrier protein should be safe, stable, highly immunogenic and more 
importantly, capable of displaying multiple epitopes efficiently. According to previous studies, 
the major subunit CfaB of ETEC CFA/I has been proved to be a good carrier [57; 58]. However, 
only limited epitopes from CFAs were included in this MEFA, and two important enterotoxins, 
LT and ST, are missing.  
Heat-labile enterotoxin has been proved to have potent immunogenicity as well as 
adjuvanticity, the property of its intracellular retrograde transportation can be exploited to deliver 
antigen through the cell membrane. These features make LT a combination of antigen, adjuvant, 
and even a delivery vehicle, which shows a great potential for vaccine development not only for 
ETEC, but also applicable for other pathogens. Many attempts have been made to reform LT to 
become an antigen carrier. Epitope mapping of LTB subunit has been completed by several 
researchers [68; 69]. But it is inappropriate to put foreign epitopes into LTB because LTB is 
crucial for cell binding and alteration of B subunit will affect its GM1 binding ability as well as 
its adjuvanticity and immunogenicity [70]. There are some researchers reported that native LTB 
alone could be used as vaccine carrier [71; 72], suggested that the adjuvanticity of LTB is 
independent of A subunit. However, intranasal administration of LTB alone only induced a 
moderate systemic and a restricted low mucosal antibody response, while the addition of LT 
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holotoxin to LTB strongly stimulated both serum antibody and systemic mucosal S-IgA response 
[73], indicating that A subunit also plays important roles in adjuvanticity and stimulation of 
mucosal immunity. The immune modulating ability of LTA is not related to its ADP-ribosylation 
activity, since non-toxic dmLT is still a potent adjuvant. Besides, a potential endoplasmic 
reticulum (ER) retention sequence (RDEL) on the C-terminal of A2 domain is believed to be 
crucial for movement of LT from the Golgi to ER [74]. Therefore, keeping an intact structure of 
LTA subunit helps to introduce antigens into the cell which is a benefit for some vaccines against 
virus and intracellular bacteria.  
 The purpose of this study is to evaluate LT enterotoxin as a carrier protein to develop 
new epitope-based subunit vaccines. To keep the immunogenicity and adjuvanticity of LT to the 
utmost, the holotoxin structure of LT is expected to be retained. Foreign epitopes will be added 
to the A1 domain of LTA subunit to minimize their effect on the structure and function of LT. 
To achieve the objective, there are two important things to figure out. The first thing is to find 
out the number of epitopes in LTA and which epitopes are the most immunogenic. The 
immunodominant epitopes will be kept in the MEFA protein so that it can still induce immune 
response against LT toxin, while the less immunogenic epitopes will be replaced by epitopes 
from other antigens. Secondly, we try to determine whether changing epitopes will influence the 
structure as well as other biological functions like toxicity and GM1 binding ability of LT. 
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Chapter 2 - Identification of immunodominant epitopes of 
enterotoxigenic Escherichia coli (ETEC) heat-labile toxin (LT) A 
subunit 
 Introduction 
Heat-labile enterotoxin is (LT) one of the toxins produced by ETEC that causing diarrhea, 
making LT an indispensable candidate for ETEC vaccines. Except for its strong immunogenicity, 
the immune-modulatory properties of LT make it an excellent adjuvant. Multiple studies on LTB 
subunit provided intensive understanding of its antigenic properties [68; 69]. Meanwhile, LTB 
has been well applied as an important component in various vaccine candidates [71; 75]. LTA 
has been proved to be a protective antigen against ETEC [76] as well as a mucosal adjuvant [35; 
73; 77]. However, there is a lack of study of roles LTA plays in activating immune response. To 
evaluate the immunogenic characteristic of LTA subunit, a preliminary epitope mapping was 
finished in this study. A total of 11 B-cell linear epitopes were predicted and each of them was 
fused into an ovalbumin carrier protein for further analysis. The immune-dominant epitopes of 
LT were determined by a series of immunoassays and a mice immunization.   
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 Materials and Methods 
 Epitope prediction and protein modeling 
B-cell linear epitopes of LTA subunit were predicted in silico using an online software 
[78]. Peptides that have highest scores were selected as epitopes. Protein models were generated 
by Phyre2 online server [79] based on their amino acid sequences and viewed through PyMOL. 
 Bacterial strains and plasmids 
Bacterial strains and plasmids used in this study were shown in Table 2.1. The epitope 
carrier protein, chicken ovalbumin, was obtained from E. coli DH5α strain 9511 which is 
constructed in a previous study [80]. Vector pET28α (Novagen, WI) and E. coli strain BL21 (GE 
Healthcare, NJ) was used to clone and express recombinant fusion proteins. Recombinant E. coli 
strains were cultured in Luria Broth (LB) medium supplemented with kanamycin (30μg/ml). 
Table 2.1 Bacterial strains used in study 1 
Strains Properties Reference 
BL21 F- ompT hsdS (rB
-, mB
-), gal dcm GE Healthcare 
9511 3×STa fusion with chicken ovalbumin in 
pET28α/DH5α Kan+ 
[80] 
9529 Ovalbumin fused LT epitope1 in pET28α/BL21 Kan+ This study 
9546 Ovalbumin fused LT epitope2 in pET28α/BL21 Kan+ This study 
9550 Ovalbumin fused LT epitope3 in pET28α/BL21 Kan+ This study 
9547 Ovalbumin fused LT epitope4 in pET28α/BL21 Kan+ This study 
9551 Ovalbumin fused LT epitope5 in pET28α/BL21 Kan+ This study 
9552 Ovalbumin fused LT epitope6 in pET28α/BL21 Kan+ This study 
9548 Ovalbumin fused LT epitope7 in pET28α/BL21 Kan+ This study 
9543 Ovalbumin fused LT epitope8 in pET28α/BL21 Kan+ This study 
9553 Ovalbumin fused LT epitope9 in pET28α/BL21 Kan+ This study 
9544 Ovalbumin fused LT epitope10 in pET28α/BL21 Kan+ This study 
9549 Ovalbumin fused LT epitope11 in pET28α/BL21 Kan+ This study 
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 Construction of plasmids 
To identify the most immunogenic epitopes of LTA subunit, each predicted epitope was 
fused to chicken ovalbumin, which has been proved to be an effective vaccine carrier protein. 
Splicing overlap extension (SOE) PCR was used to replace epitopes into the carrier protein 
(Figure 2.1). Briefly, PCR products of upstream and downstream fragments were overlapped 
through a pair of reverse complement primers which encode the epitope peptide. The overlapped 
fragments were amplified and double-digested by EagI and NcoI (New England Biolabs, MA), 
then cloned into pET28α to get pET28α-LTe1~e11. All constructed plasmids were first 
transformed into DH5α competent cells with heat shock. After PCR screening and gene 
sequencing (Genscript, NJ), positive clones were selected for following experiment. The primers 
used in this study are listed in Table 2.2. The sequences of ovalbumin carrier are shown in 
uppercase, the sequences of LT epitopes are shown in lowercase, the sequences of restriction 
sites are shown in bold. 
 
Figure 2.1 Construction of ovalbumin-LT epitope fusion genes 
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Table 2.2 Primers used in study 1  
Primers DNA sequences (5’-3’) 
Oval-upF CATGCCATGGGCGGACCCGGACCTGGTA 
Oval-downR TATCGGCCGTTAGGTCCGGGTCCTTCGT 
LT-e1F ggtgatacttgtaatgaggagacccagGATGAAGATACCCAGGCGATGCCGTTTCGC 
LT-e1R ctcattacaagtatcacctgtaattgtTTTAAACGCTTTTTCCCACAGGCCTTTAAA 
LT-e2F ggcgacaaattataccgtgctgactctagaGATGAAGATACCCAGGCGATG 
LT-e2R acggtataatttgtcgccatttgcataTTTAAACGCTTTTTCCCACAG 
LT-e3F agatgaaataaaacgttccggaggtGATGAAGATACCCAGGCGATG 
LT-e3R gaacgttttatttcatctgggggtctagagtcTTTAAACGCTTTTTCCCACAG 
LT-e4F aatgagtacttcgatagaggaactcaaGATGAAGATACCCAGGCGATG 
LT-e4R tctatcgaagtactcattatgccctctTTTAAACGCTTTTTCCCACAG 
LT-e5F agaggaacacaaaccggcGATGAAGATACCCAGGCGATG 
LT-e5R gccggtttgtgttcctctcgcgtgatcataTTTAAACGCTTTTTCCCACAG 
LT-e6F gatgacggatatgtttccacttctGATGAAGATACCCAGGCGATG 
LT-e6R ggaaacatatccgtcatcatatctTTTAAACGCTTTTTCCCACAG 
LT-e7F ccatatgaacaggaggtttctgcgGATGAAGATACCCAGGCGATG 
LT-e7R aacctcctgttcatatgggtgagggctTTTAAACGCTTTTTCCCACAG 
LT-e8F aacagggaatatagagaccggtatGATGAAGATACCCAGGCGATG 
LT-e8R gtctctatattccctgttacgatgTTTAAACGCTTTTTCCCACAG 
LT-e9F gcagaggatggttacagattagcaggtGATGAAGATACCCAGGCGATG 
LT-e9R tctgtaaccatcctctgccggagcTTTAAACGCTTTTTCCCACAG 
LT-e10F accggatcaccaagcttggagagaagaaGATGAAGATACCCAGGCGATG 
LT-e10R caagcttggtgatccggtgggaaacctgcTTTAAACGCTTTTTCCCACAG 
LT-e11F ccacaaggttgtggaaattcatcaagaacaGATGAAGATACCCAGGCGATG 
LT-e11R atttccacaaccttgtggtgcatgatgTTTAAACGCTTTTTCCCACAG 
T7-F TAATACGACTCACTATAGGG 
T7-R GCTAGTTATTGCTCAGCGG 
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 Expression of recombinant ovalbumin-LT epitope fusion protein 
E. coli BL21 was used to express recombinant proteins following a previous protocol 
[63]. A single colony from each recombinant strain was cultured in 5 ml LB medium 
supplemented with kanamycin (30 μg/ml) shaking at 37 °C overnight. Then, 2 ml of overnight 
bacterial culture was added to 200 ml 2×Yeast Extract Tryptone (YT) medium (Fisher Scientific, 
MA) supplemented with kanamycin (30 μg/ml) and shaking at 37 °C. After optical density (OD) 
value of the culture reached 0.5~ 0.7, Isopropyl β-D-1-thiogalactopyranoside (IPTG; Sigma, MO) 
was added into the culture to a final concentration of 30 μM and grew for four more hours. 
Centrifuge the culture at 12,000 rpm for 15 min to collect bacteria. Pellets were resuspended in 
10 ml bacterial protein extraction reagent (B-PER; Thermo Fisher Scientific, MA) and shaking 
for 30 min at room temperature, then the mixture was centrifuged at 12,000 rpm for 15 min at 
4 °C. Pellet was resuspended in 10 ml B-PER with vortex and pipetting. Add freshly prepared 
lysozyme to the final concentration of 200 μg/ml, and shaking at room temperature for 40 min to 
completely lyse the bacteria. Suspensions were centrifuged again and resuspended in B-PER 
supplemented with lysozyme to make sure all bacterial cell were lysed. After centrifugation, 
pellets were suspended in 100 ml 1:10 diluted B-PER, vortexed, and centrifuged. Pellets were 
washed by resuspending and vortexing with 100 ml PBS, centrifuged at 12,000 rpm for 15 min at 
4 °C. The washing step was repeated for 3 to 5 times. Final pellets were proceeded to refolding 
process. Briefly, extracted proteins were mixed with 1xIB solubilization buffer (50 mM CAPS, 
pH 11.0) supplemented with 0.3% N-lauroylsarcosine and 1 mM DTT. After incubation at room 
temperature for 40 min, suspension was centrifuged at 12,000 rpm for 20 min at room 
temperature. Solubilized proteins in supernatant were subsequently transferred to molecular 
porous membrane tubing (Spectrum Laboratories, Inc., CA) and refolded using Dialysis Buffer 
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(20 mM Tris-HCl, pH 8.5) supplemented with 0.1 mM DTT at 4 °C. After 3–4 h, protein 
samples (in tubing) were moved to Dialysis Buffer without DTT, and followed by two more 
buffer changes. Refolded recombinant proteins were collected with centrifugation at 12,000 rpm 
for 10 min at 4 °C, measured for protein concentration, aliquoted, and stored at −80 °C. Ten 
micrograms of each refolded fusion protein were analyzed in 12% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and Western Blot assay. 
 Screening epitopes with anti-CT and anti-LT serum 
The recombinant epitope fusion proteins were screened by anti-CT (Sigma, MO) rabbit 
polyclonal antibody and anti-dmLT (made in our lab) mice polyclonal antibody through two 
assays. 
For Enzyme-Linked ImmunoSorbent Assay (ELISA), each recombinant ovalbumin-LT 
epitope fusion protein (500 ng per well in 100 μl coating antigen buffer) was coated in Immulon 
2HB 96-well plates (Thermo Fisher Scientific, MA). Plates incubated at 37°C for 1 h and then 
4°C overnight were washed three times with PBS-0.05% Tween 20 (PBST). After incubation 
with 10% skim milk at 37 °C for 1 h to block uncoated sites, wells were washed three times with 
PBST and incubated with anti-dmLT or anti-CT serum at 37 °C for 1 h. Two-fold dilutions of 
primary antibodies start from 1:200 to 1:12800. Then the plates were again washed with PBST 3 
times. One hundred microliters of horseradish peroxidase (HRP) conjugated goat-anti-mouse 
IgG (for dmLT) or goat-anti-rabbit IgG (for CT) second antibodies (Sigma, MO) were diluted 
3000 times and added in each well and incubated at 37°C for 1 h. Finally, after three washes with 
PBST each well was incubated with 100 μl 3,3’,5,5’-tetramethylbezidine (TMB) Microwell 
Peroxidase Substrate (KPL, MD) at room temperature for 30 min and measured for OD650. The 
highest dilution that gave an OD reading above 0.3 after subtraction of background readings was 
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calculated (OD × dilution) for antibody titer. Antibody titers were presented in log10 value [57; 
58]. Each recombinant epitope fusion protein was tested in duplicate wells repeated for three 
times. 
For Western Blot, recombinant fusion proteins separated in SDS-PAGE gels were 
transferred to nitrocellulose membrane (GE Healthcare, NJ) and blocked with 10% skim milk 
overnight. After three washes with PBST, the membrane was then incubated with anti-dmLT or 
anti-CT serum (1:3000) at room temperature for 1 h. Again, wash the membrane with PBST 3 
times and add IRDye-labeled second antibodies goat-anti-mouse IgG (for dmLT) or goat-anti-
rabbit IgG (for CT) (1:10000; LI-COR, NE). Proteins were detected with a LI-COR Odyssey 
premium infrared gel imaging system (LI-COR) at the wavelength of 700 nm [57]. 
 Mouse immunization with ovalbumin-LT epitope fusion protein 
For each epitope, five eight-week-old female BALB/c mice (Charles River Laboratories 
International, Inc., MA) were used for immunization. Besides, five mice immunized with 
ovalbumin carrier without LT epitope and five mice immunized with sterile PBS were used as 
two control groups. Each mouse was immunized subcutaneously with 40μg (in 25μl PBS) 
refolded ovalbumin-LT epitope fusion protein and 25 μl Montanide ISA 51 VG (SEPPIC, NJ) 
adjuvant (50μl in total). Antigen and adjuvant were emulsified in a water in oil formula 
following manufacturer’s protocol. Two weeks after prime immunization, two booster injections 
at the same dose of the primary were followed in an interval of two weeks. All the mice were 
euthanized two weeks after the second booster, 0.5~ 1.0 ml blood sample was collected from 
each mouse.  Mouse immunization study complied with the Animal Welfare Act by following 
the 1996 National Research Council guidance and was approved by the Kansas State 
University’s Institutional Animal Care and Use Committee (IACUC #3800). 
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 Anti-toxin antibody titration 
Anti-toxin antibody titration was determined through ELISA following a previous 
procedure [57; 58; 63].  Recombinant LT (gifted by Dr. John Clements) was coated (200 ng per 
well) with 100 μl coating antigen buffer in wells of Immulon 2HB 96-well plates (Thermo Fisher 
Scientific, MA). After incubation with 10% skim milk at 37 °C for 1 h to block uncoated sites, 
wells were washed three times with PBST and incubated with mouse serum two-fold dilutions at 
37 °C for 1 h. Serum samples collected from immunized mice were initially diluted in 1:400 and 
then two-folded diluted till to 1: 25,600. For serum from the PBS control group, dilutions of 
1:200 were also included in ELISAs as negative control. Then the plates were again washed with 
PBST 3 times. One hundred microliters of horseradish peroxidase (HRP) conjugated goat-anti-
mouse IgG second antibodies (1:3000; Sigma) was added in each well and incubated at 37°C for 
1 h. Finally, after three washes with PBST each well was incubated with 100 μl 3,3’,5,5’-
tetramethylbezidine (TMB) Microwell Peroxidase Substrate (KPL, MD) at room temperature for 
30 min and measured for OD650. The highest dilution that gave an OD reading above 0.3 after 
subtraction of background readings was calculated (OD × dilution) for antibody titer. Antibody 
titers were presented in log10 value [57; 58]. Serum sample of each mice was tested in duplicate 
wells repeated for three times. 
 Anti-toxin antibody neutralization assay 
Serum samples pooled from five mice in each group were used for antibody 
neutralization assay with EIA cAMP kits (ENZO Life Sciences Inc., NY) in vitro. T-84 cells, a 
human colon carcinoma cell line cultured in DMEM: F12 medium (ATCC, VA) supplemented 
with 10% fetal bovine serum (FBS; Atlanta Biologicals, GA) were used in this assay. When 
incubated with LT enterotoxin, T-84 cell will produce high level of intracellular cAMP, however, 
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anti-LT antibodies can neutralize LT toxin specifically to prevent LT from stimulating 
intracellular cAMP. Therefore, it is possible to quantify neutralization activities of anti-LT 
antibodies and compare which epitope can induce neutralizing antibody most effectively. First, 
30 μl of pooled serum sample of each immunization group or the control group was incubated 
with 20 ng LT for 30 min at room temperature. Then the serum/toxin mixture was added to each 
well of a 24-microplate (Corning Inc., NY) (1x105 T-84 cells per well) and incubated in a CO2 
incubator for 3 h. Finally, T-84 cells were lysed and the supernatant was used to measure 
intracellular cAMP levels (pmol/ml) with EIA cAMP kit according to manufacturer’s 
instructions. LT alone (without serum) was used as the positive control to show enterotoxicity in 
stimulation of cAMP in T-84 cells, and culture medium only (without toxin or serum) was used 
as blank control to show a baseline of intracellular cAMP level in T-84 cells [57; 61]. Serum 
sample of each epitope was tested in duplicate wells repeated for three times. 
 Statistical analysis 
Data were analyzed using GraphPad Prism 5. Results were presented as means with 
standard deviations. Differences between groups were calculated by one-way analysis of 
variance with a confidential interval of 95%. Calculated p values of less than 0.05 were 
considered as significant difference between groups. 
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 Results 
 Eleven B-cell linear epitopes were predicted in LTA subunit 
The amino acid sequence of LTA subunit was analyzed through BepiPred with a window 
size of 13 amino acids and threshold of 0.3. A total of 11 B-cell linear epitopes that have highest 
scores were predicted and listed in Table 2.3. Among them epitope 3 has the highest score, 
followed by epitope 1, 7, 9, 10, and 11. The positions and scores of these epitopes were shown in 
Figure 2.2. Epitope 1 is on the A2 domain of LTA, while the rest 10 epitopes are on A1 domain.  
Table 2.3 B-cell linear epitopes predicted in LTA subunit  
 aa sequences Position Length 
Epitope1 TITGDTCNEETQ 193-204 12 
Epitope2 NGDKLYRADSR 1-11 11 
Epitope3 DSRPPDEIKRSGG 9-21 13 
Epitope4 RGHNEYFDRGTQ 25-36 12 
Epitope5 YDHARGTQTG 42-51 10 
Epitope6 RYDDGYVSTS 54-63 10 
Epitope7 SPHPYEQEVSA 105-115 11 
Epitope8 HRNREYRDRY 140-149 10 
Epitope9 APAEDGYRLAG 156-166 11 
Epitope10 AGFPPDHQAWREE 165-177 13 
Epitope11 HHAPQGCGNSSRT 181-193 13 
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Figure 2.2 Positions and scores of predicted epitopes 
 
 
 Structural modeling of ovalbumin-LT epitope fusion proteins 
The locations of predicted epitopes were shown in a 3D model of LTA (PDB ID:1LTA) 
(Figure 2.3) in different colors. Figure A and C display the secondary structure of LTA while B 
and D show the surface accessibility of predicted epitopes. A and B are front views while C and 
D are back views of the model. Except for epitope 2 and 6, all predicted epitopes are exposed on 
surface of LTA protein, indicating that these epitopes are more easily interacting with specific 
antibodies.  
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Figure 2.3 Locations of predicted epitopes on LTA subunit 
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 Different epitopes were recognized by anti-LT and anti-CT serum 
Recombinant ovalbumin-LT epitope fusion proteins were expressed and purified, SDS-
PAGE gel showed that the size of fusion proteins is around 34kDa, which is similar to the size of 
carrier protein (Figure 2.4). To determine whether these epitopes can be recognized by anti-
dmLT or anti-CT antibodies, ELISA and Western Blot were performed.  
Epitope 3 and 4 showed the strongest bands in Western Blot using anti-CT prime 
antibody. Although it is not quite obvious, there was a slight band against epitope 7 at around 
34kDa, while other epitope fusion proteins can not be detected by anti-CT antibody (Figure 
2.5A). All 11 epitopes showed specific bands against anti-dmLT antibody (Figure 2.5B), and 
neither antibodies recognize the carrier protein.  
All 11 epitope fusion proteins can be recognized by both anti-CT and anti-dmLT 
antibodies by ELISA. In consistent with Western Blot, anti-CT antibody preferred epitope 3 and 
4, whose titers are significantly higher than the rest of epitopes (Figure 2.6A). Epitope 7, 8, and 9 
have significant higher titers than the other epitopes when using anti-dmLT serum as prime 
antibody (Figure 2.6B). The ovalbumin carrier protein had no cross reaction with neither anti-CT 
nor anti-dmLT antibody. 
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Figure 2.4 SDS-PAGE detection of recombinant ovalbumin-LT epitope fusion proteins 
 
Figure 2.5 Western Blot detection of fusion protein with anti-CT and anti-dmLT 
 
 
Figure 2.6 ELISA detection of fusion protein with anti-CT and anti-dmLT 
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 Ovalbumin-LT epitope fusion proteins induced anti-LT antibody in mice 
Mice were immunized with ovalbumin-LT epitope fusion proteins and Montanide 
emulsion subcutaneously. Two weeks after second booster, mice were euthanized and blood was 
collected. Anti-LT antibody titers of serum samples from each mouse was tested by ELISA. 
Among all 11 epitopes, epitope 7 showed the highest antibody titer, which is significantly higher 
than all other epitopes beside epitope 3, which indicates that epitope 7 is the immune dominant 
epitope in LT. Medium antibody titers were observed in epitope 3, 9, 11, 6, and 10, only 1 to 3 
mice out of 5 have good immune responses against these epitopes. Epitope 1, 2, 4, and 5 showed 
poor immunogenicity because only low levels of antibody detected. The ovalbumin carrier 
protein failed to induce antibody against LT. 
 
A B 
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Figure 2.7 Anti-LT antibody titration  
 
 LT could be neutralized by immunized mice serum 
To determine whether antibody induced by ovalbumin-LT epitope fusion proteins have 
biological function, i.e. neutralizing LT toxin, a toxin neutralization assay was conducted. As 
shown in Figure 7, mice serum from LT epitope 7, 9, and 11 had the best toxin neutralizing 
ability, intracellular cAMP levels were significantly reduced compared to control groups. Serum 
of epitope 2, 3, 4, 6, 8, and 10 had moderate toxin neutralizing activities, while epitope 1 and 5 
can not induce neutralizing antibody in mice model, whose cAMP levels had no significant 
difference with that in carrier protein and negative control group. Positive control group without 
serum showed that 20ng LT toxin is enough to induce a significant increase of cAMP level 
compared to blank control group which had only DMEM:F12 medium.  
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Figure 2.8 Anti-LT antibody neutralization assay 
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 Discussion 
In this study, we determined that LT epitope 7 is the most immunogenic epitope. It has 
relative high score given by the epitope predicting software. Epitopes completely exposed at the 
surface of 3D model suggesting that they can be easily detected by host immune system. Epitope 
screening using anti-dmLT polyclonal serum indicated that the amount of antibody specific to 
epitope 7 is significantly higher than antibodies specific to other epitopes, thus this epitope might 
be the main target of the immune responses. Additionally, mice immunized with epitope 7 fusion 
protein produced the highest anti-LT serum IgG level, and these anti-epitope 7 antibodies were 
functional which neutralized LT toxin most effectively in vitro. These results proved the concept 
that single epitope of LTA is capable of inducing anti-LT neutralizing antibody in mice model. 
Except for epitope 7, epitope 3, 9, and 11 could also induce moderate immune response, while 
antibody titers of epitope 1, 2, 5, 6, 8, 10 were relatively lower. Therefore, these six epitopes can 
be replaced by more immunogenic foreign epitopes and epitope 7 should be retained when using 
LT as a multi-epitope fusion antigen carrier. 
As we know, LT and CT are similar in amino acid sequences, structures and 
immunomodulatory properties. There is immunogenic cross reaction between LT and CT, since 
human immunized with CT could produce immune response against both CT and LT. However, 
this cross protection seems mainly rely on antibodies targeting specific shared conformational 
structures between LT and CT which explains why anti-CT and anti-dmLT antibodies 
recognized different linear epitopes in this study. Although for each epitope, LT and CT still 
shared most part of their sequences, difference in 2-3 amino acids might completely block the 
cross reaction between LT and CT. Epitope 3, 4, and 7 can be recognized by both anti-CT and 
anti-dmLT antibodies suggested that LT and CT are highly similar in both sequences and 
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conformational structures at these regions. These shared epitopes, especially epitope 3, could be 
used to induce protection against both LT and CT. In addition, all of these conclusions were 
made based on experiments in mice model. Other models include pigs, primates, and human 
should be included in future study to confirm whether this pattern works for other different 
immune systems. 
Normally, dmLT is the best adjuvant for ETEC related subunit vaccines. But in this study, 
dmLT is not applicable because it would be hard to distinguish the anti-LT immune responses 
between dmLT and the LT epitope. Montanide ISA 51 VG, a modified mineral oil adjuvant that 
enhances humoral immune response was used as adjuvant in mice experiment. One thing need to 
be mentioned is that an inconsistency of immune responses was observed in group 6, 8, 10, and 
11. In these groups, only 1 or 2 mice showed good antibody titers while the rest of mice did not. 
The differences within these groups might be caused by individual variances of mouse reacting 
with the Montanide adjuvant. Anyway, result from epitope 7 is still quite convincing since all 5 
mice in this group showed good immune responses.  
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Chapter 3 - Significance of the A subunit epitopes in enterotoxicity 
of enterotoxigenic Escherichia coli (ETEC) heat-labile toxin (LT) 
 Introduction 
The ideal LT as a vaccine component should be non-toxic while the AB5 holotoxin 
structure remains unharmed, so that antigens can be carried through cell membrane and delivered 
into the cell without causing side effects. To utilize LT as an antigen carrier, it is necessary to 
figure out the method to detoxify LT and the location to insert foreign antigens without 
disrupting other properties of LT. Both A and B subunits are required for LT toxicity. Alteration 
the structure of either LTA or LTB will dramatically influence the toxicity of LT. LTB subunits 
indirectly contribute to LT toxicity because A subunit alone can’t get inside of the cell without 
binding to cell surface through LTB. Besides, the A2 domain of LTA plays an important role in 
intracellular transportation of LT [74]. The cell binding and intracellular transportation is 
important for a delivery platform, suggesting that the sequence of LTB and LTA2 can’t be 
altered. Therefore, LTA1 is the only option to be manipulated as an antigen carrier.  
In Chapter 2, 11 B-cell linear epitopes on LTA subunit have been predicted, and their 
immunogenic properties were analyzed. But the relationships between these epitopes with the 
structure and functions of LT are still not clear. This chapter will further explore the relationships 
between these epitopes and the toxicity of LT. Theoretically, the enzymatic function of LTA1 is 
so delicate that substitution of one or two amino acid would weaken the toxicity. Mutant LT 
derivations including LT L192G, and LTK63 have been proved to be less toxic than native LT.  
To testify whether replacing epitopes on LTA1 with foreign epitopes will influence the toxicity, 
receptor binding ability, and holotoxin structure of LT, 10 epitopes on LTA1, which were 
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predicted in Chapter 2, were substitute with a foreign epitope to construct mutant LT proteins. 
Since epitope 1 is on A2 domain, it will be not included in this part of study. 
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 Materials and Methods 
 Bacterial strains and plasmids 
Bacterial strains and plasmids used in this study were shown in Table 3.1. An E. coli 
TOP10 (Invitrogen, CA) strain 8460 [81] which contains a complete open reading frame of eltAB 
gene originated from human ETEC strains was used for plasmid construction. Vector pBR322 
(Promega, WI) and pMAL-c5X (New England Biolabs, MA) which encodes a maltose-binding 
protein (MBP) were used to construct epitope-mutated LT toxins. Recombinant E. coli strains 
were cultured in Luria Broth (LB) medium supplemented with ampicillin (100μg/ml). 
Table 3.1 Strains and plasmids used in study 2 
Strains Properties Reference 
8460 Native LT in pBR322/TOP10  [81]      
9646 LT epitope 2 mutant in pBR322/DH5α Amp+ This study 
9647 LT epitope 3 mutant in pBR322/DH5α Amp+ This study 
9648 LT epitope 4 mutant in pBR322/DH5α Amp+ This study 
9649 LT epitope 5 mutant in pBR322/DH5α Amp+ This study 
9650 LT epitope 6 mutant in pBR322/DH5α Amp+ This study 
9651 LT epitope 7 mutant in pBR322/DH5α Amp+ This study 
9652 LT epitope 8 mutant in pBR322/DH5α Amp+ This study 
9653 LT epitope 9 mutant in pBR322/DH5α Amp+ This study 
9654 LT epitope 10 mutant in pBR322/DH5α Amp+ This study 
9655 LT epitope 11 mutant in pBR322/DH5α Amp+ This study 
Plasmids   
pBR322  Promega 
pMAL-c5X  NEB 
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 Construction of plasmids 
To determine whether epitope alteration influence the toxicity and structure of the toxin, 
each epitope was substituted by an epitope (KDAQTNSSS) of maltose binding protein (MBP). 
Splicing overlap extension (SOE) PCR was used to replace or insert epitopes into the carrier 
protein (Figure 3.1). Briefly, PCR products of upstream and downstream fragments were 
overlapped through a pair of reverse complement primers which encode the epitope peptide. The 
primers used in this study are listed in Table 5. Then the overlapped fragment was amplified and 
subsequently used for enzyme digestion and ligation. For LT epitope mutant protein, NheI and 
EagI (New England Biolabs, MA) were used for digestion and vector pBR322 was used to 
express these LT mutant proteins. All constructed plasmids were first transformed into DH5α 
competent cells with heat shock. After PCR screening and gene sequencing (Genscript, 
Piscataway, NJ), positive clones were selected for following experiment. 
 
Figure 3.1 Construction of LT mutants 
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Table 3.2 Primers used in study 2 
Primers DNA sequences (5’-3’) 
pBR-NheIF TGCGGTAGTTTATCACAG 
pBR-EagIR GTCCCTGATGGTCGTCATCT 
pBR-LTe2F ACGCGCAGACTAATTCGAGCTCGagacccccagatgaaata 
pBR-LTe2R TCGAATTAGTCTGCGCGTCTTTatataatggcgatgctaa 
pBR-LTe3F ACGCGCAGACTAATTCGAGCTCGggtcttatgcccagaggg 
pBR-LTe3R TCGAATTAGTCTGCGCGTCTTTgtcagcacggtataattt 
pBR-LTe4F CGCGCAGACTAATTCGAGCTCGcaaatgaatattaatctt 
pBR-LTe4R CTCGAATTAGTCTGCGCGTCTTTtctgggcataagacctcc 
pBR-LTe5F ACGCGCAGACTAATTCGAGCTCGggctttgtcagatatgat 
pBR-LTe5R TCGAATTAGTCTGCGCGTCTTTataaagattaatattcat 
pBR-LTe6F CGCGCAGACTAATTCGAGCTCGtctcttagtttgagaagt 
pBR-LTe6R CTCGAATTAGTCTGCGCGTCTTTtctgacaaagccggtttg 
pBR-LTe7F CGCGCAGACTAATTCGAGCTCGgcgttaggtggaatacca 
pBR-LTe7R CTCGAATTAGTCTGCGCGTCTTTgctgtatacgcctaatac 
pBR-LTe8F CGCGCAGACTAATTCGAGCTCGtattacagaaatctgaat 
pBR-LTe8R CTCGAATTAGTCTGCGCGTCTTTatgtaatcgttcatcaat 
pBR-LTe9F ACGCGCAGACTAATTCGAGCTCGggtttcccaccggatcac 
pBR-LTe9R TCGAATTAGTCTGCGCGTCTTTagctatattcagatttct 
pBR-LTe10F CGCGCAGACTAATTCGAGCTCGgaaccctggattcatcat 
pBR-LTe10R CTCGAATTAGTCTGCGCGTCTTTtgctaatctgtaaccatc 
pBR-LTe11F CGCGCAGACTAATTCGAGCTCGacaattacaggtgatact 
pBR-LTe11R CTCGAATTAGTCTGCGCGTCTTTatgaatccagggttcttc 
 
 Detection of mutant LT  
To testify whether LT is still normally expressed after changing one of its epitope, 
Western Blot was used to detect toxin secreted in the supernatant of bacterial culture. Strains 
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containing 10 mutant LT plasmids and 8460 which expresses native LT toxin as positive control 
were cultured in 10 ml LB supplemented with 100μg/ml ampicillin overnight. A native DH5α 
was also cultured as negative control. Then the culture was centrifuged at 12,000 rpm for 10 
minutes to remove bacteria cells. Around 9 ml culture supernatant was subsequently filled in 
dialysis membrane tubing (Spectrum Laboratories, Inc., CA) and concentrated with Aquacide II 
(EMD Millipore, MA) for 8 h to a final volume of about 1 ml. Concentrated samples were then 
used for Western Blot. Similar to the procedure in Chapter 2, protein samples were transferred 
from SDS-PAGE gels to nitrocellulose membrane and blocked with 10% skim milk overnight. 
The membrane was then incubated with anti-LTA serum (1:3000) at room temperature for 1 h 
and IRDye-labeled goat-anti-mouse IgG second antibodies (1:10000; LI-COR, NE). Proteins 
were detected with a LI-COR Odyssey premium infrared gel imaging system (LI-COR) at the 
wavelength of 700 nm. 
 GM1 binding of mutant LT 
To assess the ability of mutated LT proteins binding to GM1 receptor, the GM1-ELISA 
was conducted [82]. 96-well Plates were coated at 4 °C overnight with 100 μl monosialo 
ganglioside GM1 (4μg/ml) in each well and then washed by PBST 3 times. Overnight bacterial 
culture of each LT epitope mutant strain was adjusted to same OD value (OD600=1.0) and then 
centrifuge at 12,000 rpm for 10 minutes. 100 μl supernatant which contains mutated LT protein 
was added to each well and incubated at 37 °C for 1 h. The supernatant of strain 8460 which has 
wild type LT was used as positive control, while supernatant of native DH5α was used as 
negative control. After washed with PBST 3 times, the GM1- LT complex was blocked at 37 °C 
for 1 h with 10% skim milk in PBST and washing with PBST 3 times again. Serial dilutions of 
anti-LTA mouse polyclonal serum (Sigma, MO) were prepared and added to the wells. Plates 
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were incubated at 37 °C for 1 h and after washing, 100 μl 1:3000 dilutions of HRP goat anti-
mouse IgG second antibody (Sigma, MO) was added to each well. Following steps are same with 
ELISA protocols described in epitope screening and antibody titration. Each LT mutant was 
tested in duplicate wells and repeated for three times. 
 Mutant LT toxicity assay 
Toxicity of mutated LT proteins was tested by cAMP ELISA with a direct cyclic AMP 
enzyme immunoassay (EIA) kit according to the manufacturer's instruction [57; 61]. Briefly, 1 × 
105 T-84 cells were seeded and cultured in each well of a 24-well plate. After removing the 
Dulbecco's modified Eagle medium (DMEM:F12; ATCC, VA), 75 μl overnight culture growth 
supernatant from each strain was added to each well (in duplicate). Cells were lysed with 200 μl 
(per well) 0.1 M HCl after 3 h of incubation. One hundred microliters of lysis product were 
mixed with conjugates and antibody reagents supplied in the kit, and the mixture was added to 
each well of a supplied EIA plate. After incubation on a shaker (500 rpm) at room temperature 
for 2 h, plates were washed and then incubated with p-nitrophenyl phosphate (pNpp) (disodium 
salt) substrate solution (100 μl per well) for 1 h. The OD was measured at 405 nm after adding 
stop solution. Each LT mutant was tested in duplicate wells and repeated for three times. 
 Statistical analysis 
Data were analyzed using GraphPad Prism 5. Results were presented as means with 
standard deviations. Differences between groups were calculated by one-way analysis of 
variance with a confidential interval of 95%. Calculated p values of less than 0.05 were 
considered as significant difference between groups. 
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 Results 
 Mutant LT proteins were expressed and secreted 
In Figure 3.2, Western Blot using anti-LTA antibody showed that 10 LT mutants can be 
normally expressed and secreted in DH5α. The bands at around 37kDa indicate the holotoxin 
structure of LT is not influenced by replacing one of its epitope on LTA subunit. Bands below 
20kDa confirmed the normal expression of LTA subunit in these mutants. The culture 
supernatant of 8460 which secrets native LT and commercialized CT toxin (Sigma, MO) were 
used for positive controls. 
Figure 3.2 Western Blot detection of secreted mutated LT proteins 
  
 LT mutants bind to GM1 
The culture supernatant containing secreted LT mutants was used to determine the GM1 
binding abilities of these LT mutants by GM1 ELISA. All LT mutants showed strong GM1 
binding abilities that had no significant difference with native LT expressed by 8460 (Figure 3.3), 
indicated that replacing any epitope on LTA subunit does not affect the receptor binding ability 
of LT. The supernatant of DH5α used as a negative control here showed no GM1 binding at all. 
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Figure 3.3 GM1 binding of LT mutant proteins 
 
 LT mutants lose enterotoxicity 
To test whether LT mutants have reduced toxicity, a toxicity assay using T84 cells was 
conducted. It is clear that intracellular cAMP concentration indicates LT toxicity, a direct cAMP 
enzyme immunoassay (EIA) kit was used to quantify intracellular cAMP level of T84 cells after 
treating with bacterial supernatant which contain secreted mutant LT toxins. All 10 mutant toxins 
failed to induce high levels of cAMP, while same volume of culture supernatant of 8460 induced 
extremely high concentration of cAMP which is out of upper limit that the kit can detect. Cells 
treated with 10ng of cholera toxin had a significantly increased cAMP concentration of about 40 
pmol/ml, while cells treated with supernatant of DH5α and cell culture medium still have normal 
cAMP levels. The results suggest that changing a single epitope on LTA subunit eliminates 
almost all the toxicity of LT. 
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Figure 3.4 Enterotoxicity assay of mutated LT proteins 
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 Discussion 
In this study, we complete a preliminary evaluation of the characteristics of mutant LT 
proteins. After replacing an epitope on LTA1, the enzymatic activity of LTA subunit was 
seriously damaged, but the holotoxin structure and the cell binding ability of B subunits were 
unaffected. Hence, LT could be used as a safe platform carrying foreign antigens to provide 
broadly protection against multiple virulence factors or even different pathogens.  
 Interestingly, using pBR322 vector, LT can be secreted in DH5α with complete 
holotoxin structure. Although the expression level is low, it is still detectable by immunoassays 
and enough to induce a significant toxicity response in T84 cells. These findings might indicate 
an easier way to evaluate LT based vaccines which purified protein is not required. The secretion 
of LT suggested that the LT is not only suitable for subunit vaccine, but also applicable for live 
or vectored vaccines. When combined with the MEFA strategy, epitopes of STa and CFAs can 
be introduced into this platform to generate a powerful ETEC vaccine. Foreign antigens of 
interest from one specific or several different pathogens can be also included to develop vaccine 
candidates against other diseases. The chimeric LT can be either purified as recombinant subunit 
antigen, or expressed in a live vector strain. All of these possibilities might bring more 
innovations to vaccine development in future. 
However, there are some problems need to be solved. Replacing only one epitope of 
LTA1 at a time did not affect the protein structure of LT. But LT structure might be unstable 
when multiple epitopes are introduced, because there might be a certain limit for alteration. It is 
necessary to figure out how these epitopes influence the structure of LT. The relationship 
between LT structure and its adjuvanticity and the mechanisms of LT adjuvanticity are still 
unknown. The adjuvanticity of these mutant LT are yet to be further determined in animal 
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experiments. Future studies on LT adjuvanticity may help explain the mechanisms of how LT 
stimulate host immune system. 
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